Presentation is loading. Please wait.

Presentation is loading. Please wait.

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer  Paul J. Speicher, MD, Zachary W. Fitch,

Published byMegan Simon Modified over 5 years ago

Similar presentations

Presentation on theme: "Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer  Paul J. Speicher, MD, Zachary W. Fitch,"— Presentation transcript:

1 Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer  Paul J. Speicher, MD, Zachary W. Fitch, MD, Brian C. Gulack, MD, Chi-Fu J. Yang, MD, Betty C. Tong, MD, David H. Harpole, MD, Thomas A. D’Amico, MD, Mark F. Berry, MD, Matthew G. Hartwig, MD  The Annals of Thoracic Surgery  Volume 102, Issue 3, Pages (September 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Survival estimates for patients diagnosed with clinical T1-3N1 non-small cell lung cancer, stratified by use of induction chemotherapy (blue line) vs surgery first (red line), (A) before adjustment and (B) after propensity matching. (CI = confidence interval.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Survival estimates for patients diagnosed with tumors larger than 4 cm, stratified by use of induction chemotherapy (blue line) vs surgery first (red line), (A) before adjustment and (B) after propensity matching. (CI = confidence interval.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Survival estimates for patients diagnosed with T3 tumors, stratified by use of induction chemotherapy (blue line) vs surgery first (red line), (A) before adjustment and (B) after propensity matching. (CI = confidence interval.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer  Paul J. Speicher, MD, Zachary W. Fitch,"

Similar presentations

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.
Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma  Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma  Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.

Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,
Constantin Stefanidis, MD, Albert M

Constantin Stefanidis, MD, Albert M
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Kanika Trehan, MD, Xun Zhou, MD, Stephen C. Yang, MD 

Kanika Trehan, MD, Xun Zhou, MD, Stephen C. Yang, MD 
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Trevor Williams, MD, MPH, Brian C

Trevor Williams, MD, MPH, Brian C
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Chi-Fu Jeffrey Yang, MD, Derek Y. Chan, BSE, Paul J

Chi-Fu Jeffrey Yang, MD, Derek Y. Chan, BSE, Paul J
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery 

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery 
Castigliano M. Bhamidipati, DO, MS, George J

Castigliano M. Bhamidipati, DO, MS, George J

Similar presentations

Ads by Google